Phenobarbital for Canine Idiopathic Epilepsy: Prescribing Patterns, Pharmacometrics, and TDM

Bottom line.

• Phenobarbital remains the most widely prescribed first-line antiseizure drug (ASD) for dogs with idiopathic epilepsy (IE), with a reported efficacy of 60–93% in reducing seizure frequency.
• Therapeutic drug monitoring (TDM) with a target serum phenobarbital concentration of 20–35 µg/mL is essential; the drug has a narrow therapeutic index and high interindividual pharmacokinetic variability.
• A 2026 pharmacometrics study established a two-compartment population PK model that enables model-informed precision dosing (MIPD) for phenobarbital in dogs, improving upon fixed-dose empirical regimens.
• A 2026 US retrospective study of 853 epileptic dogs in primary care found phenobarbital was the most commonly prescribed first-line ASD (34.9%), followed by levetiracetam (31.3%), zonisamide (22.9%), and potassium bromide (11.1%).
• Hepatotoxicity (idiosyncratic and dose-dependent) is the most serious long-term risk; baseline and periodic liver enzyme monitoring (ALP, ALT, total bilirubin, bile acids) is mandatory.
• This is a clinician-facing evidence summary. It is not a treatment protocol; confirm drug dosing, TDM intervals, and hepatotoxicity monitoring against current formularies and your hospital protocols.

Clinical facts

• Drug class: Barbiturate antiseizure drug; enhances GABA-A receptor chloride conductance and reduces neuronal excitability.
• Indications: Idiopathic epilepsy in dogs (first-line); also used as add-on or sole ASD in structural epilepsy. No veterinary-specific FDA approval for oral epilepsy in dogs; commonly used off-label in cats with caution.
• Pharmacokinetics: Oral bioavailability ~90%; half-life in dogs approximately 40–90 hours (mean ~65 hours); auto-induction of hepatic enzymes occurs over the first 4–6 weeks, meaning steady-state serum concentrations are lower than initially predicted. Allow 2–4 weeks before TDM at any given dose.
• Therapeutic target range: 20–35 µg/mL (some references extend to 40 µg/mL; values >45 µg/mL associated with increased toxicity risk).
• Starting dose: Typically 2–3 mg/kg PO q12h; adjust based on TDM results and clinical response. Doses up to 5 mg/kg q12h may be required in some dogs.
• Adverse effects: Sedation and ataxia (common early, often resolve), polyphagia, polydipsia, polyuria, weight gain (dose-dependent); hepatotoxicity (idiosyncratic or dose-dependent, monitor with periodic LFTs and fasting/2-hour postprandial bile acids); bone marrow suppression reported rarely.
• Drug interactions: Phenobarbital induces CYP450 enzymes — reduces serum concentrations of many co-administered drugs including ciclosporin, metronidazole, and theophylline; may reduce serum levetiracetam concentrations (see Saint-Maxent 2024 for quantitative data).

Managing an epileptic dog in your clinic this week?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, TDM guidance, and adverse effect recognition to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Prescribing patterns in US primary care (2026)

A large retrospective study by Pompermaier et al. (2026, Frontiers in Veterinary Science, PMC12926901) analysed 853 dogs with IE diagnosed at Banfield Pet Hospital primary care practices across the US between 2020–2023.¹ Phenobarbital was the most commonly prescribed first-line ASD at 34.9% of cases, followed by levetiracetam (31.3%), zonisamide (22.9%), and potassium bromide (11.1%). The study found that prescribing patterns generally aligned with ACVIM consensus recommendations, including the recommendation for TDM: serum phenobarbital concentration monitoring was performed in 77.5% of phenobarbital-treated dogs in the cohort. The median age at IE diagnosis was 3.3 years, and males accounted for 60.6% of cases; Labrador Retrievers, Chihuahuas, and Siberian Huskies were most represented breeds.

Pharmacometrics and model-informed precision dosing (2025)

A 2025 pharmacometrics study by Vitorino Carvalho et al. (Frontiers in Veterinary Science, PMC12440713) used nonlinear mixed-effects (NLME) modelling in 121 serum samples from 100 phenobarbital-treated dogs at steady state to build a two-compartment population PK model, validated in an additional 50-dog cohort.² The model identified weight and age as significant covariates for volume of distribution and clearance, respectively. Simulations using the model demonstrated that standard fixed empirical starting doses of 2.5 mg/kg q12h frequently fail to achieve the 20–35 µg/mL therapeutic target range in smaller and older dogs, while potentially exceeding it in larger younger dogs. The authors proposed MIPD using this model as a tool to individualize dose selection and earlier attainment of therapeutic concentrations, reducing the trial-and-error inherent in TDM-guided step-up dosing. This represents a clinically actionable advance for practices seeking to optimize phenobarbital initiation.

Efficacy evidence base

Across controlled trials and observational studies, phenobarbital achieves at least a 50% reduction in seizure frequency in approximately 60–85% of dogs with IE when serum concentrations are maintained within the therapeutic range. Comparative data from the Gristina et al. 2023 study (JAVMA, PMID 36965471) — already cited in the levetiracetam-canine-epilepsy article — confirmed phenobarbital as the historical comparator: 51 of 100 IE dogs in that cohort received phenobarbital as primary ASD. The Pompermaier 2026 data show that phenobarbital remains the numerically most prescribed first-line ASD in US primary care in the current era, despite the availability of newer agents, reflecting its well-established evidence base, affordability, and oral bioavailability.

How this fits clinical practice

Phenobarbital is the benchmark first-line ASD for canine IE against which all newer drugs are compared. Its efficacy is well-established and its cost is low relative to levetiracetam or anti-mAbs; however, the combination of auto-induction, interindividual PK variability, and narrow therapeutic index means that TDM is not optional. The practical consequence of the Vitorino Carvalho 2025 pharmacometrics data is that weight- and age-adjusted individualized dosing, rather than universal flat starting doses, will likely improve the proportion of dogs achieving therapeutic concentrations by the first planned recheck. Practitioners should anticipate dose titration needs especially in small-breed dogs, where weight-adjusted dosing may push concentrations into the toxic range more readily, and in geriatric patients where clearance may be reduced. Hepatotoxicity monitoring — at minimum liver enzymes and bile acids at baseline, 6 months, and annually — remains mandatory for any dog on chronic phenobarbital therapy; the threshold for biliary assessment should be low if ALP or ALT rise disproportionately to the ASD induction effect.

Always confirm specific dosing, TDM target ranges, and hepatotoxicity monitoring protocols against current formulary and your hospital standards.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Pompermaier E, Morrison JA, Stabile F, De Risio L. 2026. Retrospective study on canine idiopathic epilepsy treatment in primary care practices in the United States. Front Vet Sci 13:1723038. https://pmc.ncbi.nlm.nih.gov/articles/PMC12926901/
2. Vitorino Carvalho A, et al. 2025. Pharmacometrics modeling and simulation to assist phenobarbital dose optimization in dogs. Front Vet Sci 12:1644003. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1644003/full

Changelog

• 2026-07-02: First published.